drugset
drugset / Trial / NCT01370876

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01370876 ↗

Phase 2 Terminated 46 enrolled Nang Kuang Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer and to assess the safety profile of these treatment regimen.

Timeline

Start
2010-09
Primary completion
2011-08
Completion
2012-05

Outcome

Outcome not reported

Stopped: “company policy”

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule — Other
Subject fluorouracil Small molecule — Intravenous

Indications

head and neck cancer